彩虹天堂
Lv3
380 积分
2023-01-05 加入
-
Tumor microenvironment-mediated immune profiles and efficacy of anti-PD-L1 antibody plus chemotherapy stratified by DLL3 expression in small-cell lung cancer
1天前
待确认
-
Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer
1天前
已完结
-
Delta-like ligand 3 in small cell lung cancer: Potential mechanism and treatment progress
4天前
已完结
-
Targeting the Notch signaling pathway and the Notch ligand, DLL3, in small cell lung cancer
4天前
已完结
-
Emerging Strategies for the Treatment of Small Cell Lung Cancer: A Review
11天前
已完结
-
Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer
11天前
已完结
-
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial
11天前
已完结
-
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial
12天前
已完结
-
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial
12天前
已完结
-
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial
12天前
已完结